Masimo (MASI)
(Delayed Data from NSDQ)
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Zacks News
Medical Products' Oct 30 Earnings Roster: MCK, MASI & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.
Masimo (MASI) Reports Next Week: What You Should Expect
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain HMS Holdings (HMSY) Stock For Now
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.
Cerner (CERN) Set to Improve Patient Experience With New Deal
by Zacks Equity Research
The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.
Here's Why You Should Hold Onto Cerner (CERN) Stock for Now
by Zacks Equity Research
Cerner (CERN) keeps its 2019 revenue guidance intact; expects improvement in bookings.
NextGen's (NXGN) Population Health Picked by Ohio-Based UH
by Zacks Equity Research
NextGen's (NXGN) EHR services are expected to enhance patient outcomes at UH.
Fresenius Medical Launches 4008A Dialysis Machine in China
by Zacks Equity Research
Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.
Sleep Apnea Market Gains Momentum: 3 Stocks in Focus
by Trina Mukherjee
Sleep apnea - a significant health issue in the United States - is a booming market, thereby reflecting promising investment prospects.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome
by Zacks Equity Research
Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.
Varian's ProBeam Now Available in Multi-Room Configuration
by Zacks Equity Research
Shandong Cancer Hospital in China selects Varian (VAR) to equip its new research center with the ProBeam Proton Therapy system.
Varian's AI-Driven Ethos Solution to Boost Global Cancer Care
by Zacks Equity Research
Varian (VAR) expects the Ethos launch to boost its Oncology Systems segment.
Medidata (MDSO) Collaborates With Mapi Research to Boost Rave
by Zacks Equity Research
Medidata's (MDSO) latest collaboration is expected to solve major eCOA implementation struggles in the pharmaceutical industry.
Ecolab's (ECL) Nalco Water Opens Customer Experience Center
by Zacks Equity Research
Ecolab (ECL) expects Nalco's water technologies to reduce freshwater usage by 20%.
Masimo (MASI) Boosts O3 Platform With Three New Indices
by Zacks Equity Research
Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
Accuray (ARAY) slashes fiscal 2020 revenue guidance owing to tariffs in China.
Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
HealthEquity (HQY) gains from solid segmental contributions in second-quarter fiscal 2020.
HealthEquity Acquires WageWorks, To Make Notable Investments
by Zacks Equity Research
HealthEquity (HQY) expects to complete its $80-100 million investment program within 24-36 months from now.
Cooper Companies (COO) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Cooper Companies (COO) gains from solid segmental contributions in fiscal Q3.
Varian's ProBeam Compact System Picked by University of Miami
by Zacks Equity Research
Varian (VAR) sees notable developments in its Proton Solutions business of late.
DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
DexCom (DXCM) has various favorable factors to maintain the current high.
Has Masimo (MASI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?